CXCL8 and colon adenocarcinoma: inhibits IL-8 release in LPS-treated human colon adenocarcinoma (HT-29) cells, and these Bifidobacterium cell species may be good agents for preventing inflammation via neutralizing Gram-negative endotoxins and improving intestinal health [10, 57].